Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients with Chronic HCV Infection

作     者：Xiaoqing Liu Peng Hu Xiaoqing Liu;Peng Hu

作者机构：Department of Infectious DiseasesInstitute for Viral HepatitisThe Key Laboratory of Molecular Biology for Infectious Dis-easesChinese Ministry of EducationThe Second Affiliated Hospital of Chongqing Medical UniversityChongqingChina 

出 版 物：《Journal of Clinical and Translational Hepatology》 (临床与转化肝病杂志（英文版）)

年 卷 期：2021年第9卷第1期

页      面：125-132页

核心收录：

学科分类：1004[医学-公共卫生与预防医学(可授医学、理学学位)] 100401[医学-流行病与卫生统计学] 10[医学] 

基　　金：supported in part by the Kuanren Talents Program of the Second Affiliated Hospital of Chongqing Medical University 

主　　题：Hepatitis C Mavyret Glecaprevir Pibrentasvir Treatment outcome 

摘      要：Hepatitis C virus(HCV)infection is a major cause of end-stage liver disease,including decompensated cirrhosis and hepatocellular *** 95%of patients with HCV infection have achieved sustained virologic response at 12 weeks under the treatment of several pan-genotypic regimens approved for patients with HCV *** glecaprevir/pibrentasvir(G/P)regimen has some features that distinguish it from others and is the only 8-week regimen approved for treatment-naive patients and patients experienced in regimens containing(peg)interferon,ribavirin,and/or sofosbuvir,without an HCV NS3/4A protease inhibitor or NS5A inhibitor(except those with genotype 3).This review aims to summarize the efficacy and safety of G/P in HCV-infected patients from clinic trials and real-world studies,including those who have historically been considered difficult to cure.